Abits
ABTS
Bit Origin
BTOG
TeraWulf
WULF
BIGG DIGITAL ASSETS INC
BBKCF
NEPTUNE DIGITAL ASSETS CORP
NPPTF
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.